February 25, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2506495

Tecovirimat for the Treatment of Mpox

Listen to this summary

The authors aimed to evaluate the clinical efficacy of tecovirimat for treating adults with laboratory-confirmed clade II mpox in a phase 3 randomized trial. The results indicated no significant differences in clinical resolution, pain reduction, or viral DNA clearance between the tecovirimat and placebo groups, suggesting that tecovirimat does not provide a therapeutic benefit for this condition.

Jason Zucker, William A Fischer, Lu Zheng, Caitlyn McCarthy, Pooja T Saha, Arzhang Cyrus Javan, Alex Greninger, Matthew M Hamill, Kieron Leslie, Kristina M Brooks, Jonathan Berardi, Davey Smith, Lara Hosey, Grace Aldrovandi, Kathie Ferbas, Cheryl Day, Rachel A Bender Ignacio, Robert Bolan, Marshall J Glesby, Raphael J Landovitz, Anne F Luetkemeyer, Juan Sierra Madero, Rajesh T Gandhi, Sharon Nachman, Joe Eron, Judith S Currier, Timothy Wilkin, STOMP/A5418 Investigators

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play